Stories about Central nervous system

Subscribe to Central nervous system

16.12.2020 – 10:00

Grünenthal Group
Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development

Aachen (ots) - Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain. The Phase I trial will include 76 healthy participants. ...

more
20.10.2020 – 16:39

Technische Universität München
Coronavirus: door opener facilates cell entry

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36263/ NEWS RELEASE How the virus enters the cell Coronavirus: Neuropilin-1 could open the door to the inside of the cell The protein neuropilin-1 facilitates SARS CoV-2 cell entry. A research team including ...

more
19.10.2020 – 08:01

Zentiva
Zentiva Reinforces Its Presence In Greece To Better Serve Greek People

Prague (ots/PRNewswire) - Zentiva reinforces its presence in Greece by signing a partnership with the company Lavipharm for representation, promotion, and distribution of its pharmaceutical products in Greece. With an established presence in Europe, Zentiva continues to strengthen its capabilities and service offering for people, by partnering with Lavipharm. "We are ...

more
02.10.2020 – 09:31

Stada Arzneimittel
STADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson's disease

Press release STADA expands specialty footprint through acquisition of innovative therapy for treating advanced Parkinson’s disease - STADA is submitting approval applications to launch the new therapy in major European markets. Approvals are ...
One document
more
15.09.2020 – 08:58

Stada Arzneimittel
STADA's US partner Supernus submits NDA for apomorphine infusion pump

Press release STADA‘s US partner Supernus submits NDA for apomorphine infusion pump - STADA’s US commercial partner Supernus files New Drug Application (NDA) with US Food and Drug Administration for an apomorphine infusion pump (SPN-830). - The NDA filing for SPN-830 for continuous treatment of ...
One document
more
11.09.2020 – 14:00

Merck KGaA
New MAVENCLAD® Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting Highlight Rapid Onset of Action and Compelling Post-Approval Safety

Darmstadt, Germany (ots/PRNewswire) - In MAGNIFY-MS, patients experienced a rapid onset of action from end of Month 1 that was significant in all study periods versus baseline Post-approval safety analysis showed no increased risk of viral respiratory infections and lower rates of malignancy than in the clinical ...

more
09.09.2020 – 07:00

UCB Pharma
Final Phase II Results for UCB's Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) Published in Blood Advances

Brussels (ots/PRNewswire) - - Phase II data demonstrated clinically meaningful platelet count increases with meaningful decreases in IgG concentration - Rozanolixizumab's subcutaneous route of administration shows potential to deliver targeted individualized patient care for people living with Primary Immune ...

more
03.09.2020 – 14:00

Merck KGaA
Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ...

more
31.07.2020 – 08:30

Ethypharm
Ethypharm's UK manufacturing site passes its 1st U.S. FDA inspection

St-Cloud, France (ots/PRNewswire) - The Ethypharm Group today announced that its facility located in Romford (Sussex, UK) has successfully passed its first U.S. Food and Drug Administration (FDA) inspection. Now waiting for the approval of its partner's marketing authorization, the site is gearing up to start supplying sterile pre-filled syringes (PFS) to the U.S. market by year end. This successful FDA inspection ...

more
29.07.2020 – 07:00

UCB Pharma
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease

Brussels (ots/PRNewswire) - - UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further ...

more
27.07.2020 – 07:10

UCB Pharma
UCB Half Year Report 2020

Brussels (ots/PRNewswire) - - UCB's resilient product portfolio drives continued company growth - Revenue increased to EUR 2.6 billion and net sales to EUR 2.5 billion, both +12%, +9% CER or +10% at CER and adjusted for divestitures respectively - Underlying profitability (adj. EBITDA) was EUR 783 million (+8%, 0% CER) or a ratio of 30% - Ra Pharma acquisition closed early April, Engage Therapeutics acquired in June, co-promotion agreement for Cimzia® with Ferring in July - ...

more
16.06.2020 – 08:00

The International Osteoporosis Foundation (IOF)
$The International Osteoporosis Foundation (IOF): New Capture the Fracture® partnership aims for 25% reduction in the incidence of hip and vertebral fractures due to osteoporosis by 2025$
New Capture the Fracture® partnership aims for 25% reduction in the incidence of hip and vertebral fractures due to osteoporosis by 2025

more
05.06.2020 – 07:25

UCB Pharma
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...

more
28.05.2020 – 10:00

Merck KGaA
Merck and Twitch Join Forces on World Multiple Sclerosis Day to Connect People Living With MS

Darmstadt, Germany (ots/PRNewswire) - - Merck and Twitch collaborate on World MS Day to increase understanding of the impact of multiple sclerosis (MS) - Livestream event with Twitch influencers on May 30 will raise awareness and money for the MS International Federation and help connect people affected by the disease, in line with official World MS Day theme MS ...

more
10.04.2020 – 15:00

UCB Pharma
UCB's General Meeting of Shareholders

Brussels (ots/PRNewswire) - - Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 - Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic - No physical presence at General Meeting allowed and votes can only be submitted by ...

more
02.04.2020 – 15:34

UCB Pharma
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab, UCB's FcRn targeting ...

more
10.02.2020 – 13:35

Technische Universität München
Major project for Munich neurosciences

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 71 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35908/ High resolution images: https://mediatum.ub.tum.de/1537625 NEWS RELEASE CLINSPECT-M: Clinical mass spectrometry center for molecular brain research Major project for Munich neurosciences In a joint ...

more
10.12.2019 – 01:45

UCB Pharma
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...

more
10.10.2019 – 09:38

UCB Pharma
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

Brussels and Cambridge, Massachusetts (ots/PRNewswire) - - Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - ...

more
24.06.2019 – 14:00

Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...

more
24.06.2019 – 11:35

Gedeon Richter Pharma GmbH
Experts Discuss: 'Social Egg Freezing' - Does It Alleviate or Increase the Pressure Among Women to Have a Baby Early?

Vienna (ots/PRNewswire) - A panel of leading fertility experts discuss fertility preservation considerations for women on their fertility journey Experts have gathered at a Gedeon Richter-sponsored panel discussion to debate the pressure paradox of egg freezing, a procedure which is on the rise in Europe.1 In the ...

more
30.05.2019 – 10:01

Merck KGaA
Merck Pioneers New Efforts to See MS From the Inside Out

Darmstadt, Germany (ots/PRNewswire) - Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate ...

more
30.04.2019 – 14:05

Merck KGaA
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019

Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Merck, a leading science and technology company, today announced that data from ...

more
30.03.2019 – 01:02

Merck KGaA
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy ...

more
25.03.2019 – 12:04

Merck KGaA
MAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland

Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...

more
03.01.2019 – 08:01

NORGINE B.V. and KOREA PHARMA CO., LTD.
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...

more
18.10.2018 – 07:01

UCB Pharma
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...

more
11.10.2018 – 19:31

Merck KGaA
Global Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis

Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S media - Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those impacted by MS Merck, a leading science and ...

more
09.10.2018 – 10:15

Helmholtz Zentrum München
Satiety in 3D

Many overweight people lack the feeling of being full. It was long thought that this was due to the disrupted transport of the satiety hormone leptin to the brain. That is not the case, as a group of scientists from Helmholtz Zentrum München has now shown in the 'International Journal of Obesity'. The work was made possible by a new 3D imaging technique that allows tracking the path ...
Would you like to read the message online? This way!

more
14.07.2015 – 18:48

Zambon GmbH
Zambon Expands in Europe Acquiring Nigaard

Milan (ots/PRNewswire) - The deal will speed up the commercialization of Xadago(R) for the treatment of Parkinson's Disease Nigaard is a pharmaceutical company well established in Denmark, Norway, Sweden, Iceland and Finland Zambon S.p.A., an international pharmaceutical company strongly committed to the Central Nervous System (CNS) therapeutic area and the Respiratory area with a focus on Rare Diseases, announced today ...

more

12Next